Azitra, Inc. Files Q1 2025 10-Q
Ticker: AZTR · Form: 10-Q · Filed: May 13, 2025 · CIK: 1701478
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Azitra's Q1 2025 10-Q is in, showing standard operations. No major news yet.
AI Summary
Azitra, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus is on the development of novel treatments for respiratory diseases. The filing details its financial position and operational activities during the first quarter of 2025, with no specific dollar amounts or significant events highlighted in the provided snippet.
Why It Matters
This filing provides investors with an update on Azitra's financial health and operational progress in its pursuit of new respiratory disease treatments.
Risk Assessment
Risk Level: medium — Biotech companies like Azitra often carry medium to high risk due to the inherent uncertainties in drug development and regulatory approval processes.
Key Players & Entities
- Azitra, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date
- 2834 (other) — Standard Industrial Classification for Pharmaceutical Preparations
- BRANFORD, CT (location) — Company's business and mailing address
FAQ
What is Azitra, Inc.'s primary business focus?
Azitra, Inc. is focused on pharmaceutical preparations, as indicated by its SIC code [2834].
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 13, 2025.
What is Azitra, Inc.'s principal business address?
Azitra, Inc.'s principal business address is 21 Business Park Drive, Suite 6, Branford, CT 06405.
What is Azitra, Inc.'s SEC file number?
Azitra, Inc.'s SEC file number is 001-41705.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Azitra, Inc. (AZTR).